Dimensional Fund Advisors LP Has $18.18 Million Position in Inogen, Inc. (NASDAQ:INGN)

Dimensional Fund Advisors LP lifted its stake in Inogen, Inc. (NASDAQ:INGN – Get Rating) by 11.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 748,876 shares of the medical technology company’s stock after purchasing an additional 74,175 shares during the period. Dimensional Fund Advisors LP owned 3.27% of Inogen worth $18,183,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in Inogen by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 2,565,014 shares of the medical technology company’s stock worth $83,157,000 after acquiring an additional 42,755 shares during the period. Federated Hermes Inc. grew its holdings in Inogen by 155.8% during the 2nd quarter. Federated Hermes Inc. now owns 599,813 shares of the medical technology company’s stock worth $14,503,000 after acquiring an additional 365,311 shares during the period. Renaissance Technologies LLC grew its holdings in Inogen by 15.1% during the 1st quarter. Renaissance Technologies LLC now owns 336,400 shares of the medical technology company’s stock worth $10,906,000 after acquiring an additional 44,100 shares during the period. FMR LLC grew its holdings in Inogen by 1.2% during the 2nd quarter. FMR LLC now owns 332,536 shares of the medical technology company’s stock worth $8,040,000 after acquiring an additional 4,085 shares during the period. Finally, Northern Trust Corp grew its holdings in Inogen by 7.1% during the 2nd quarter. Northern Trust Corp now owns 228,097 shares of the medical technology company’s stock worth $5,516,000 after acquiring an additional 15,174 shares during the period. Institutional investors and hedge funds own 95.93% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on INGN. Needham & Company LLC lowered their target price on shares of Inogen from $36.00 to $26.00 and set a “buy” rating for the company in a report on Friday, February 24th. William Blair lowered shares of Inogen from an “outperform” rating to a “market perform” rating in a report on Tuesday, January 17th. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, Inogen has an average rating of “Hold” and a consensus price target of $26.00.

Inogen Stock Down 1.1 %

Shares of INGN stock opened at $14.64 on Wednesday. Inogen, Inc. has a 12-month low of $14.51 and a 12-month high of $35.67. The firm has a market capitalization of $336.28 million, a price-to-earnings ratio of -4.00 and a beta of 1.05. The firm has a fifty day moving average of $21.59 and a 200-day moving average of $22.76.

Inogen (NASDAQ:INGN – Get Rating) last posted its quarterly earnings data on Thursday, February 23rd. The medical technology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.03. The business had revenue of $88.09 million for the quarter, compared to analysts’ expectations of $89.70 million. Inogen had a negative net margin of 22.21% and a negative return on equity of 8.72%. The firm’s revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.01) EPS. Research analysts expect that Inogen, Inc. will post -2.47 earnings per share for the current year.

Inogen Company Profile

(Get Rating)

Inogen, Inc engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home.